Diabetes Therapy
Studies add new findings to diabetes therapy body of knowledge
Published in Cardiovascular Week, January 30th, 2006
Study 1: Muraglitazar increases risk of death and major adverse cardiovascular events in patients with type 2 diabetes.
According to a report from the United States, "Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting two distinct families of PPARs (alpha and gamma) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a U.S. Food and Drug Administration (FDA) advisory committee on September 9, 2005, resulting in a vote of 8:1...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2006-01-30)
More Articles from Cardiovascular Week
- Atherosclerosis
Fas ligand gene transfer increases vulnerability of atherosclerosis - Atherosclerosis
MCP-1 and eotaxin levels are not indicators of atherosclerosis or myocardial infarction - Coronary Artery Disease
Base serum levels of inflammatory markers may be influenced by endogenous sex hormones - Pediatric Cardiology
Acetyl-L-carnitine may exert cardiac neurotrophic action - Statins
IB ultrasound indicates fluvastatin improved arterial sclerosis - Acute Myocardial Infarction
Adjunctive intravenous adenosine improves microvascular reflow after primary coronary stenting - More from this issue of Cardiovascular Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
